Spark Therapeutics

Prevent Blindness Declares May as First-ever Inherited Retinal Disease (IRD) Genetic Testing Awareness Month

Retrieved on: 
Wednesday, April 24, 2024
Education, Paratriathlon, University, Blood, Birth defect, Retina, RP, Social media, Diagnosis, Stargardt disease, Stargardt, Marketing, Strabismus, Genetic, Johnson & Johnson, Gene, Spark Therapeutics, Choroid, Research, Visual impairment, Genetic testing, Pediatric ophthalmology, Disease, Visual Science, Patient, Eye, Cone dystrophy, MBA, Vision, Student, Therapy, Organization, IRD, Pharmaceutical industry

CHICAGO, April 24, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has designated May as "Inherited Retinal Disease (IRD) Genetic Testing Awareness Month," expanding its previous IRD and Genetic Testing Awareness Week initiative. The group is providing a variety of tools to promote awareness and education for IRDs and the importance of genetic testing, including a free webinar, expert and patient videos, shareable social media graphics, and fact sheets in English and Spanish. IRD Genetic Testing Awareness Month is supported by funding from Johnson & Johnson, and Spark® Therapeutics.

Key Points: 
  • Prevent Blindness expands IRD and genetic testing awareness initiative to educate patients on various forms of IRDs, and the importance of genetic testing to confirm diagnosis and possible treatments.
  • CHICAGO, April 24, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has designated May as "Inherited Retinal Disease (IRD) Genetic Testing Awareness Month," expanding its previous IRD and Genetic Testing Awareness Week initiative.
  • ET, the National Center for Children's Vision and Eye Health at Prevent Blindness will be hosting the free webinar, " Pathway to Diagnosis: Genetic Testing for Inherited Retinal Diseases ."
  • To register for the "Pathway to Diagnosis: Genetic Testing for Inherited Retinal Diseases" webinar, visit PreventBlindness.org/IRD-webinar-2024.

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Supplies, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, Science, Culture, Broad Institute, Cell, Massachusetts General Hospital, Partner (business rank), Environment, Trust, RNP, MIT, Spark Therapeutics, Patient, Harvard University, Nature Biotechnology, Tissue, Head, Protein, Therapy, Former, Safety, Royal Naval Patrol Service, FDA, Management

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.
  • The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes.
  • “The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer.
  • In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

Retrieved on: 
Thursday, March 21, 2024
HCC, Research, AML, Logic, Partnership, Spark Therapeutics, SAN, Patient, Gene, SNTI, Acute myeloid leukemia, Doctor of Philosophy, IND, Investment, Investigational New Drug, Therapy, Hepatocellular carcinoma, FDA, Food, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • SENTI-202 for AML: In December 2023, Senti Bio announced the IND application for SENTI-202 was cleared by the U.S. Food and Drug Administration (“FDA”).
  • Cash, Cash Equivalents and Short-term Investments: As of December 31, 2023, Senti Bio held cash, cash equivalents and short-term investments of $35.9 million.
  • G&A Expenses: General and administrative expenses were $9.3 million for the fourth quarter of 2023, compared to $9.8 million for the same period in 2022.
  • Net Loss: Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023.

BioPhy Appoints Scott Kobayashi as Senior Vice President of Sales to Accelerate Strategic Expansion

Retrieved on: 
Tuesday, April 2, 2024
Health, Technology, Health Technology, General Health, Artificial Intelligence, Pharmaceutical, Biotechnology, Organization, Growth, Pfizer, Fluor, Spark Therapeutics, Patient, AI, EY, Senior, Kobayashi, Clinical trial, Therapy, Drug development, Ecosystem, FDA, Pharmaceutical industry

BioPhy, an innovative AI drug development platform, today announced the appointment of Scott Kobayashi as Senior Vice President of Sales.

Key Points: 
  • BioPhy, an innovative AI drug development platform, today announced the appointment of Scott Kobayashi as Senior Vice President of Sales.
  • In this newly created role, Kobayashi will spearhead BioPhy's expansion in life sciences, public-private healthcare partnerships, financial services, and the public domain.
  • Prior to this, he held pivotal consulting positions at pharmaceutical industry giants Pfizer, Genentech, and Fluor, specializing in business expansion, partnerships, and development strategies.
  • “BioPhy has set itself apart from other biotech solutions with remarkable results in predicting and guiding clinical trial success.

SAPA-GP Hosted the 2024 Annual Conference Highlighting the Innovating Biopharma Frontier

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Health informatics, Informatics, COVID 19, McKinsey & Company, COVID, Conference, Data science, Spark Therapeutics, AI, Volunteering, Section, MBA, Yale School of Medicine, Therapy, Process, Drug development, Yale school, Multimedia, Proposition, Jazz Pharmaceuticals

On March 9, 2024, SAPA-GP ( https://sapagp.org/ ) hosted its 22nd Annual Conference at the Sheraton Valley Forge Hotel, northwest of Philadelphia.

Key Points: 
  • On March 9, 2024, SAPA-GP ( https://sapagp.org/ ) hosted its 22nd Annual Conference at the Sheraton Valley Forge Hotel, northwest of Philadelphia.
  • Fangning Zhang, MBA, Partner at McKinsey & Company, delivered the conference opening keynote speech “Path towards Value Creation – China Biopharma Innovation Trends”.
  • “Our conference has been very successful in capturing the latest trends foretelling the direction of biopharma industry.
  • The 2024 SAPA-GP Annual Conference was a great gathering of life scientists, pharmaceutical experts, and business leaders from diverse backgrounds, experiences, and accomplishments.

Pathway to Cures Announces First Entrepreneur in Residence

Retrieved on: 
Monday, March 11, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Health, Philanthropy, Fund Raising, Foundation, Other Health, Disease, Coagulopathy, Sickle cell disease, Heredity, Spark Therapeutics, Rush University Medical Center, Entrepreneur in residence, Knowledge, Mortality, Baxalta, EIR, Doctor of Philosophy, MD, MBA, Therapy, Anemia, Blood

Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.

Key Points: 
  • Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.
  • Dr. Valentino most recently served as President and CEO of the National Bleeding Disorders Foundation (NBDF) and was instrumental in bringing Pathway to Cures into reality.
  • Pathway to Cures is the venture philanthropy fund of the NBDF focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • “My role as Entrepreneur in Residence for Pathway to Cures will be to provide guidance into the consideration and support of new opportunities for catalyzing transformative therapies and cures.

Smart Immune appoints key new members to its Board of Directors

Retrieved on: 
Friday, February 16, 2024
Transfer, Research, Infection, Growth, National Cancer Institute, Immunology, Treatment, Gesellschaft mit beschränkter Haftung, Therapy, Chemical industry in India, Development, Immune system, Roche, Amgen, Dow Chemical Company, Novartis, Farmitalia, Dow, Lazard, XPath, Medical research, Spark Therapeutics, ADC, Patient, Sanofi

Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.

Key Points: 
  • Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.
  • Karine Rossignol, CEO and Co-founder of Smart Immune, said: “We are delighted and proud to welcome such distinguished experts to the Board, led by Markus Goebel as our new Chairman.
  • We are grateful to our outgoing Chairman for his 5-year commitment and support to Smart Immune.”
    Markus Goebel, CEO and Founder of M&G Advisors and Chairman of Smart Immune’s Board of Directors, said: “I am thrilled to join and lead the Board of Smart Immune.
  • He is on the Boards of Halozyme, ADC Therapeutics and Aprea Therapeutics and now an Observer on the Board of Directors at Smart Immune.

NAVEGA THERAPEUTICS APPOINTS CAROL GREVE-PHILIPS CHIEF BUSINESS OFFICER

Retrieved on: 
Tuesday, February 13, 2024
Erythromelalgia, SAN, Spark Therapeutics, Therapy, Genzyme, Chronic pain, SCN9A, CIRM, Peripheral neuropathy, NIH, Pharmaceutical industry

SAN DIEGO, Feb. 13, 2024 /PRNewswire/ -- Navega Therapeutics, a privately-held early-stage pharmaceutical company developing epigenetic gene therapies, today announced the appointment of Carol Greve-Philips as Chief Business Officer.

Key Points: 
  • SAN DIEGO, Feb. 13, 2024 /PRNewswire/ -- Navega Therapeutics, a privately-held early-stage pharmaceutical company developing epigenetic gene therapies, today announced the appointment of Carol Greve-Philips as Chief Business Officer.
  • Ms. Greve-Philips brings 35 years of business development expertise to Navega as the company pursues development and commercialization agreements for its lead program, NT-Z001—an epigenetic gene therapy modulating SCN9A (Nav1.7).
  • She has led negotiations for collaborations, partnerships, mergers and acquisitions for biotech companies specializing in rare disease and gene therapy.
  • "Navega is thrilled to welcome Carol to our leadership team," said CEO Dr. Ana Moreno .

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Retrieved on: 
Monday, January 29, 2024
Drug, Conditional sentence, Spark Therapeutics, Translation, Patient, Therapy, Employment, Paratriathlon, AAV, Universities of Lille, Innovation, Pfizer, LUNA, AMD, Adverum Biotechnologies, Drug discovery, CNS, Pharmaceutical industry

REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer.

Key Points: 
  • REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer.
  • “On behalf of the entire team at Adverum, I am delighted to welcome Dr. Corbau as the newest member of our executive leadership team.
  • Dr. Corbau joins Adverum from GenEdit, where he served as Chief Scientific Officer.
  • Prior to joining GenEdit, Dr. Corbau progressed from Vice President of Research to Chief Scientific Officer at Freeline, a clinical stage company developing AAV-vector mediated systemic gene therapies for chronic diseases.

Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors

Retrieved on: 
Thursday, January 25, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Transfer, Spark Therapeutics, Biochemistry, Therapy, Biology, Molecular biology, University, Immunology, Medical research, Doctor of Philosophy, Drexel University, Huber loss, Pharmaceutical industry

Dr. Federico Mingozzi previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer.

Key Points: 
  • Dr. Federico Mingozzi previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer.
  • Federico brings over 25 years of experience in gene therapy, immunology, as well as biochemistry and molecular biology in academia and industry.
  • Federico has participated in numerous clinical trials targeting metabolic and neuromuscular diseases, hereditary blindness, and coagulation disorders.
  • Khalil Barrage, ad interim Chair of Sensorion's Board of Directors, said: "We are delighted to welcome Federico Mingozzi as new director.